Sanofi

Ablynx N.v.

Eric Lorent

Sigrid Cornelis

Ann Brigé

Heidi Rommelaere

Bruno Dombrecht

Melanie Rieger

Timothy Soos

Bernd Weigle

Klaus Erb

John Edward Park

Christian Asbrand

Nadine Biesemann

Karen Heyninck

Shanna Van Zwam

The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.

Nucleic acids encoding polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP

The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory and/or autoimmune disease, and specifically rheumatoid arthritis. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF-α and at least two ISVDs bind to IL-6. The present disclosure also provides nucleic acids, vectors and compositions.

Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α

Methods of treating asthma with polypeptides targeting IL-13 and TSLP

The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF&#x3b1; and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.

Polypeptides comprising immunoglobulin single variable domains targeting TNFA and IL-23

Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP

Growing community of inventors

Zwijnaarde, Belgium

Eric Lorent